EDITAS MEDICINE, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
EDITAS MEDICINE, INC. (EDIT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.10% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-03-05
- EDITAS MEDICINE, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.10%.
- EDITAS MEDICINE, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.20%.
- EDITAS MEDICINE, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.10%, a 141.67% decline from fiscal 2021.
- EDITAS MEDICINE, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.24%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -0.10% 10-K · filed 2025-03-05 | |
| 2023-12-31 | -0.20% 10-K · filed 2025-03-05 | |
| 2022-12-31 | -0.10% 10-K · filed 2024-02-28 | -0.08% 10-K · filed 2023-02-22 |
| 2021-12-31 | 0.24% 10-K · filed 2023-02-22 | |
| 2020-12-31 | -0.10% 10-K · filed 2022-02-24 | |
| 2019-12-31 | -0.10% 10-K · filed 2021-02-26 | |
| 2018-12-31 | -0.10% 10-K · filed 2021-02-26 | 0.60% 10-K · filed 2019-03-01 |
| 2017-12-31 | -0.90% 10-K · filed 2020-02-26 | -2.10% 10-K · filed 2018-03-08 |
| 2016-12-31 | -3.60% 10-K · filed 2019-03-01 | |
| 2015-12-31 | -17.90% 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |